BUZZ-India's Dr Reddy's Laboratories falls with key drug "nearing the cliff"

Shares of Dr. Reddy's Laboratories REDY.NS down 4.5% at 1,232 rupees, top loser on benchmark Nifty 50 .NSEI

Co misses Q3 FY25 profit misses estimates and warns of drop in key product Lenalidomide's sales in H2 of FY26

Lenalidomide is a generic of Bristol-Myers's cancer drug Revlimid

Nuvama says "As gRevlimid is nearing the cliff, investor attention is focused on how DRL offsets the gRevlimid impact on earnings"; adds key product approvals is critical

Already weak Lenalidomide sales of led to 11% sequential decline in REDY's Q3 North America sales

Jefferies notes increased competition in North America

Session's loss trims 12 month stock price gain to 5.07%